Chronic News and Research

RSS

BSD Medical awarded two grants under QTDP Program

BSD Medical Corporation announced today that it has received the maximum award provided by the U.S. government for a single program for two separate grants under the Qualifying Therapeutic Discovery Project ("QTDP") Program.

10 Nov 2010

Stressed out Americans

The American Psychological Association’s (APA) have released the results of the 2010 Stress in America survey that shows up the long-term impact that chronic stress could have on physical and emotional health and the health of the families. The survey was conducted by Harris Interactive in August 2010. It showed some worrying trends of stress among parents as well as children.

9 Nov 2010

ARIAD reports $20.4 million net loss for third quarter 2010

ARIAD Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2010 and provided an update on corporate developments.

9 Nov 2010

Semafore's SF1126 for B-cell chronic lymphocytic leukemia granted FDA orphan drug designation

Semafore Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's SF1126 product candidate for the treatment of B-cell chronic lymphocytic leukemia (CLL). In April 2010, the Company initiated an expansion of its ongoing Phase I clinical study into this disease setting. SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of both phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR).

9 Nov 2010

REF donates $24 million in innovative RA research

The American College of Rheumatology Research and Education Foundation today announced it has raised nearly $28 million, and funded $24 million, in RA research through its Within Our Reach: Finding a Cure for Rheumatoid Arthritis campaign - putting the Foundation two million from its initial $30 million goal.

9 Nov 2010

Psychologists discover that social interaction influences individual's sensitivity to physical pain

Psychologists at the University of Toronto have shown that the nature of a social interaction has the ability to influence an individual's sensitivity to physical pain. The discovery could have significant clinical implications for doctor-patient relationships and the general well-being of an individual on a daily basis.

9 Nov 2010

March of Dimes honors professor who linked fetal malnutrition to chronic adult disease

The world-renowned physician and professor who pioneered the theory linking fetal malnutrition to chronic adult disease will receive the March of Dimes Agnes Higgins Award for outstanding achievement in the field of maternal-fetal nutrition.

9 Nov 2010

Priaxon and Technical University Munich partner to develop anti-infective agents against infectious diseases

Priaxon AG, Munich, and the University Hospital Rechts der Isar (Technical University Munich) announce their cooperation for the development of new, highly selective anti-infective agents against a novel protein target class of widely spread infectious diseases. Their joint project is supported in the framework of the top cluster support project of the German Federal Ministry of Education and Research, coordinated by BioM GmbH.

9 Nov 2010

Angiotech reports $59.0 million total revenue for third quarter 2010

Angiotech Pharmaceuticals, Inc. today announced that it had released its financial results for the third quarter ended September 30, 2010.

9 Nov 2010

Food insecurity may cause problem for diabetic patients living on fixed incomes

The economic recession impacts many aspects of our lives including an increase incidence of food insecurity. This can have serious consequences for those suffering from chronic illnesses like diabetes.

9 Nov 2010

Endeca, eHealth Ontario partner to implement chronic disease management system

Endeca Technologies, Inc., a search and business intelligence (BI) company, today announced that eHealth Ontario, an agency of the Government of Ontario, has selected Endeca and commenced work on the chronic disease management system (CDMS) and portal project previously announced in August 2010. Endeca, working with its partners, will assist with the design, build, and implementation of the system that will be used initially to better manage diabetes care throughout the province.

9 Nov 2010

Children with JIA face increase risk of developing cancer

Children with juvenile idiopathic arthritis have a two to threefold increased risk of developing cancer compared to similarly-aged children without JIA, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta. The same study also reported no cases of cancer in children with JIA who were exposed to anti-TNF therapy.

9 Nov 2010

DHA protects brain tissue and promotes recovery in acute ischemic stroke

Research led by Dr. Nicolas Bazan, Boyd Professor, Villere Chair, and Director of the Neuroscience Center of Excellence at LSU Health Sciences Center, has shown that Docosahexaenoic acid (DHA), a component of fish oil, is a powerful therapeutic agent that can protect brain tissue and promote recovery in an experimental model of acute ischemic stroke, even when treatment is delayed by up to five hours.

9 Nov 2010

Mystic awarded $245,000 QTDP grant for VersiDoser Delivery Platform

Mystic Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of advanced precision ophthalmic and intranasal delivery technologies for drugs and biologics, today announced that it has been awarded a non-taxable grant of approximately $245,000 related to its VersiDoser™ Delivery Platform under the Qualifying Therapeutic Discovery Project (QTDP) program included in the Patient Protection and Affordable Health Care Act of 2010.

9 Nov 2010

Research reveals body’s defence mechanism against snail fever

Scientists have made a significant discovery about how the body defends itself against snail fever, a parasitic worm infection common in developing countries.

9 Nov 2010

Study explains link between morbid obesity and metabolic syndrome

Scientists have found that the fat cells and tissues of morbidly obese people and animals can reach a limit in their ability to store fat appropriately. Beyond this limit several biological processes conspire to prevent further expansion of fat tissue and in the process may trigger other health problems.

9 Nov 2010

Combination treatment with methotrexate and prednisone achieves remission in newly-developed RA

People with newly-developed rheumatoid arthritis or undifferentiated arthritis may be able to achieve remission, with continued drug therapy, after four months of treatment with methotrexate and prednisone, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

9 Nov 2010

Inspiration receives two grants under QTDP program to advance development of IB1001, OBI-1 products

Inspiration Biopharmaceuticals, Inc. today announced the Company was awarded two grants, totaling $488,958, under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP).

9 Nov 2010

SIMPONI injection improves inflammation, structural damage in RA patients

Magnetic resonance imaging (MRI) analyses from two Phase 3 clinical trials showed that once every four week subcutaneous injections of SIMPONI (golimumab) 50 mg plus methotrexate resulted in statistically significant improvements in markers of inflammation and structural damage in patients with active rheumatoid arthritis (RA) compared with placebo plus methotrexate.

9 Nov 2010

CorMatrix receives $2.3 million grants under QTDP program to advance ECM technology

CorMatrix Cardiovascular, Inc., a medical device company dedicated to developing and delivering unique extracellular matrix (ECM) biomaterial devices that harness the body's innate ability to repair damaged cardiovascular tissue, today announced that the Company has been awarded $2.3 million in grants under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program to advance the development of their unique ECM technology.

9 Nov 2010